|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Serum HDL cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Serum total cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Allergic rhinitis (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The AR and LAR groups showed considerable olfactory epithelial damage and suppression of OMP expression compared with the control group.
|
31743968 |
2020 |
|
Encephalomyelitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that inflammation in the olfactory bulb of EAE-affected mice is associated with the downregulation of some olfactory signal transduction genes, particularly olfactory marker protein and stomatin-like 3, which may lead to olfactory dysfunction in an animal model of human multiple sclerosis.
|
30853826 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Knockdown of Fzd7 or using inhibitors of Wnt/Fzd (OMP-18R5/Vantictumad) decreased GC cell stemness, characterized as a decrease of spheroid formation ability and expression of stemness regulators.
|
31733054 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Here, we use inhibitors of Wnt/Fzd (OMP-18R5/vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and <i>ex vivo</i> organoid cultures.
|
30622113 |
2019 |
|
Solid Neoplasm
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
|
30591982 |
2019 |
|
Stomach Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Here, we use inhibitors of Wnt/Fzd (OMP-18R5/vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and <i>ex vivo</i> organoid cultures.
|
30622113 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Knockdown of Fzd7 or using inhibitors of Wnt/Fzd (OMP-18R5/Vantictumad) decreased GC cell stemness, characterized as a decrease of spheroid formation ability and expression of stemness regulators.
|
31733054 |
2019 |
|
Encephalomyelitis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis of olfactory marker protein (OMP) levels showed that OMP expression was significantly downregulated in the olfactory mucosa of EAE rats.
|
29557516 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
This yeast-type mechanism of OMP generation is different from the earlier proposed VDAC-hexokinase-mediated voltage generation of cancer-type, associated with the mitochondrial outer membrane.
|
28888364 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Porcupine (PORCN), RSPO3, WNT2B, FZD5, FZD10, ROR1, tankyrase and β-catenin are targets of anti-WNT signaling therapy, and ETC-159, LGK974, OMP-18R5 (vantictumab), OMP-54F28 (ipafricept), OMP-131R10 (rosmantuzumab), PRI-724 and UC-961 (cirmtuzumab) are in clinical trials for cancer patients.
|
28731148 |
2017 |
|
Solid Neoplasm
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
|
28954784 |
2017 |
|
Allergic rhinitis (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of OMP in olfactory mucosa is downregulated in AR mice with olfactory dysfunction.
|
29075337 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Effects of OMP-52M51 treatment on tumor cell migration and tumor angiogenesis were evaluated with chemotaxis and HUVEC tube formation assays.
|
31676012 |
2019 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
OMP-A2G1 alone inhibited tumor growth of both PCa cell lines to a greater extent than docetaxel alone.
|
31099068 |
2019 |
|
Superficial ulcer
|
0.010 |
Biomarker
|
disease |
BEFREE |
The eosinophil count, OMP-positive cells and epithelial erosion in olfactory mucosa collected during ESS were compared with the postoperative olfactory function.
|
31438745 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
OMP-A2G1 alone inhibited tumor growth of both PCa cell lines to a greater extent than docetaxel alone.
|
31099068 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
OMP-A2G1 alone inhibited tumor growth of both PCa cell lines to a greater extent than docetaxel alone.
|
31099068 |
2019 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Effects of OMP-52M51 treatment on tumor cell migration and tumor angiogenesis were evaluated with chemotaxis and HUVEC tube formation assays.
|
31676012 |
2019 |
|
Skin Erosion
|
0.010 |
Biomarker
|
disease |
BEFREE |
The eosinophil count, OMP-positive cells and epithelial erosion in olfactory mucosa collected during ESS were compared with the postoperative olfactory function.
|
31438745 |
2019 |
|
Mantle cell lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A MCL mouse model was used to assess the activity of OMP-52M51 in vivo.
|
31676012 |
2019 |
|
Prolactinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, patients with prolactinoma lacked OMP expression in tumor tissues with hyperactivated ERK1/2 signaling.
|
29622766 |
2018 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Study of serum bactericidal and splenic activity of Total-OMP- CagA combination from Brucella abortus and Helicobacter pylori in BALB/c mouse model.
|
29709690 |
2018 |